치주질환 치료제 시장 : 제품별, 유형별, 유통 채널별 - 세계 예측(2024-2032년)

The Periodontal Therapeutics Market size will grow at 7.7% CAGR during 2024-2032, driven by the rising prevalence of periodontal diseases. According to a WHO Oral Health report published in March 2023, severe periodontal ailments are estimated to impact approximately 19% of the global adult population. Factors such as poor oral hygiene, smoking, and systemic health issues like diabetes contribute to the growing burden of these diseases. As a result, there is a surge in demand for effective therapeutic solutions, prompting significant investment in the development and delivery of advanced periodontal treatments.

The emergence of personalized treatment plans is a significant trend shaping the market. Advances in dental diagnostics and patient data analysis are enabling practitioners to tailor treatments based on individual patient profiles, including their genetic makeup, disease severity, and overall health conditions. This shift towards personalized care enhances treatment efficacy by addressing specific needs and preferences of patients, improving outcomes and satisfaction. Personalized treatment plans often incorporate a combination of targeted therapies, advanced diagnostics, and customized preventive measures, making periodontal care more effective and patient centric.

The periodontal therapeutics industry is classified based on product, type, distribution channel, and region.

The local antibiotic therapy segment will grow rapidly through 2032. Local antibiotic therapy involves the direct application of antimicrobial agents to the periodontal pocket to control bacterial infections and reduce inflammation. This approach allows for targeted treatment, minimizing systemic side effects and enhancing the overall effectiveness of periodontal care. Recent advancements in local antibiotic formulations and delivery mechanisms, such as controlled-release systems, are expected to drive growth in this segment.

The aggressive periodontal disease segment will witness decent growth through 2032. Aggressive periodontal disease, characterized by rapid attachment loss and bone destruction, poses a serious challenge to oral health. This condition requires prompt and effective therapeutic interventions to prevent severe consequences, including tooth loss. The increasing incidence rate is driving demand for advanced treatment options tailored to managing this severe form of periodontitis. Therapies aimed at controlling the disease's progression and promoting tissue regeneration are crucial in addressing the needs of patients with aggressive periodontal conditions.

Europe periodontal therapeutics industry will witness robust growth through 2032, driven by a combination of factors. The region's well-established healthcare infrastructure and high standards of dental care contribute to the increasing adoption of advanced periodontal treatments. European countries are also experiencing a rising incidence of periodontal diseases, which is prompting greater investment in therapeutic solutions. Moreover, ongoing R&D efforts are leading to the introduction of innovative products and technologies for disease management, further fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of periodontal diseases
    • 3.2.1.2 Increasing awareness about oral health
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Technological advancements in dentistry
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited awareness and education for oral health
    • 3.2.2.2 Stringent regulatory policies
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Local antibiotic therapy
  • 5.2.1 Minocycline hydrochloride
  • 5.2.2 Doxycycline hyclate
  • 5.2.3 Chlorhexidine gluconate
  • 5.2.4 Metronidazole benzoate
  • 5.2.5 Tetracycline hydrochloride
• 5.3 Systemic antibiotic therapy
  • 5.3.1 Minocycline hydrochloride
  • 5.3.2 Doxycycline hyclate
  • 5.3.3 Metronidazole benzoate

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gingivitis
• 6.3 Chronic periodontal disease
• 6.4 Aggressive periodontal disease
• 6.5 Necrotizing periodontal disease
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Drug stores
• 7.5 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Align Technology, Inc.
• 9.2 Bausch Health Companies Inc.
• 9.3 Cadila Healthcare Ltd.
• 9.4 Colgate-Palmolive Company
• 9.5 Danaher Corporation
• 9.6 Den-Mat Holdings LLC
• 9.7 Dentsply Sirona
• 9.8 Dexcel Pharma Technologies Ltd.
• 9.9 GlaxoSmithKline plc
• 9.10 Henry Schein, Inc.
• 9.11 Hoffmann-La Roche Ltd.
• 9.12 Johnson & Johnson Services, Inc.
• 9.13 Kaken Pharmaceutical Co., Ltd.
• 9.14 Pfizer Inc.
• 9.15 Procter & Gamble Co.
• 9.16 Straumann Holding AG
• 9.17 Sunstar Suisse SA
• 9.18 Teva Pharmaceutical Industries Ltd.
• 9.19 Zimmer Biomet Holdings, Inc.
• 9.20 3M Company